Zepzelca Approved for Lung Cancer in United Kingdom
The UK's MHRA has approved Zepzelca in combination with atezolizumab as first-line maintenance therapy for extensive-stage small cell lung cancer. The approval follows clinical trial data.
PharmaMar's partner Immedica announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Zepzelca® (lurbinectedin) in combination with atezolizumab. This new treatment is indicated for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following initial therapy with atezolizumab, carboplatin, and etoposide.
The approval provides a new therapeutic option for a patient group with limited treatment choices. Zepzelca's approval is based on key clinical trial findings demonstrating its efficacy and safety in this specific patient population.
PharmaMar's European partner, Immedica, will handle the marketing and distribution of Zepzelca. The drug had previously received marketing authorization from the European Medicines Agency (EMA) for the same indication, with EMA serving as the reference regulator for the MHRA approval process.
The approval of this drug combination in the United Kingdom marks a significant advancement in the treatment of extensive-stage small cell lung cancer. The company anticipates further insights into the treatment's accessibility and patient outcomes.